| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1987.5.1.141 |
| P698 | PubMed publication ID | 3543234 |
| P2093 | author name string | G Tognoni | |
| E Ballatori | |||
| F Roila | |||
| M Tonato | |||
| D Donati | |||
| R Passalacqua | |||
| M Bella | |||
| C Basurto | |||
| D Morsia | |||
| F DiCostanzo | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Italy | Q38 |
| methylprednisolone | Q417222 | ||
| metoclopramide | Q421095 | ||
| P304 | page(s) | 141-149 | |
| P577 | publication date | 1987-01-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. | |
| P478 | volume | 5 |
| Q51030970 | A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. |
| Q42528919 | A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy |
| Q51741239 | A pilot study of metoclopramide, dexamethasone, diphenhydramine and acupuncture in women treated with cisplatin. |
| Q40126451 | A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan |
| Q48363175 | A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. |
| Q36911183 | Advances in the management of cytotoxic drug-induced nausea and vomiting |
| Q45226083 | Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy |
| Q40673130 | Antiemetics in cancer chemotherapy: historical perspective and current state of the art. |
| Q68781175 | Assessment of nausea |
| Q41174885 | Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis |
| Q34582576 | Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimens |
| Q54280745 | Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment |
| Q33284409 | Controlling cancer chemotherapy-induced emesis |
| Q35899456 | Depression in adolescents and young adults with cancer. |
| Q33996151 | Drug therapy for gynaecological cancer in older women |
| Q46653304 | Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. |
| Q69299648 | GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting |
| Q41035158 | Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. |
| Q54406441 | Issues in antiemetic therapy. |
| Q41932365 | Issues in the measurement of nausea |
| Q36564254 | Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary |
| Q40740167 | Methodological issues in antiemetic studies |
| Q68435561 | Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis |
| Q30570659 | Pattern of prophylaxis administration for chemotherapy-induced nausea and vomiting: an analysis of city-based health insurance data |
| Q88504521 | Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis |
| Q37199907 | Present Role of Corticosteroids as Antiemetics |
| Q51737323 | Randomized crossover comparison of high-dose intravenous metoclopramide versus a five-drug antiemetic regimen. |
| Q40387103 | Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities |
| Q57483443 | Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study |
| Q39453505 | Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis |
| Q48065428 | Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it. |
| Q72522017 | [Antiemetic treatment and chemotherapy: general review] |
| Q83944098 | [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research] |
Search more.